Vivek Ramaswamy Founder of Roivant Sciences, a company that buys shelved drug candidates into separate subsidiaries; co-founder of Strive Asset Management; 2024 presidential candidate and 2026 Republican nominee for Ohio governor Founder · Capital · $1–10B cost 2 headwinds 1

← browse

Founder · Capital · Biotechnology · Finance · $1–10B

Vivek Ramaswamy

Founder of Roivant Sciences, a company that buys shelved drug candidates into separate subsidiaries; co-founder of Strive Asset Management; 2024 presidential candidate and 2026 Republican nominee for Ohio governor · b. 1985 · Cincinnati, Ohio

professional-classtwo-parentCincinnati, Ohio

Roivant Sciences Strive Asset Management QVT Financial

Cost of failure 2 / 10

soft landingnothing to catch a fall

Headwinds 1 / 10

clear runagainst the current

Two calls made by hand, not formulas. how we score →

Summary

The son of Indian immigrants, he went from Harvard to a biotech hedge fund and reportedly had about $15 million before law school ended.

In 2014 he started Roivant with roughly $100 million from QVT and other investors. Forbes puts him at $2.3 billion, mostly from Roivant.

Coded record

industryBiotechnology · Finance

talenthigh

connectionswell-connected

outcome size$1–10B · band 5

path typeFounder · Capital

childhood householdtwo-parent

immigrant generationsecond-gen

educationgraduate degree

credential fundingscholarship

startup capitalprior-high-income

took outside investmentyes

kept ownershipyes

public scrutinyjournalistic

ⓘ Hover any row for its definition.

Subject cooperation: public-only · last reviewed 2026-10-11

Where they worked

Roivant Sciences Founder; CEO until January 2021, then executive chairman until February 2023 · 2014–2023 founder past Strive Asset Management Co-founder and executive chairman · 2022–2023 founder past QVT Financial Hedge fund employee, later partner co-managing a biotech portfolio · 2007–2014 past

How it happened

iCincinnati, immigrant parents

Ramaswamy was born in 1985 in Cincinnati, Ohio. His parents came from Palakkad district in Kerala, India. Wikipedia says his father was an engineer at General Electric and his mother a geriatric psychiatrist who worked for Merck and Schering-Plough. He graduated as valedictorian of St. Xavier High School in 2003. Sources consulted don't say how many siblings he has beyond that, and don't establish family income.

iiHarvard, then a hedge fund

He earned a biology degree summa cum laude from Harvard in 2007 and co-founded a small student-networking company, Campus Venture Network, the same year; it was sold to the Kauffman Foundation in 2009. From 2007 to 2014 he worked at the hedge fund QVT Financial, where he ended up as a partner co-managing a biotech portfolio. Wikipedia reports that he claimed a net worth of about $15 million in 2013, before he finished law school.

iiiYale Law while still at QVT

He took a J.D. at Yale Law School, finishing in 2013, and won a Paul & Daisy Soros Fellowship for New Americans in 2011. Who paid for Harvard isn't established in the sources consulted.

ivRoivant

Turning point

In 2014 he founded Roivant Sciences in Bermuda. Per Wikipedia, it got nearly $100 million in startup capital from QVT, his employer, and investors including RA Capital and D.E. Shaw. So the founding money was other people's, not his savings. The idea was to buy drug candidates that big pharma had shelved, such as GSK's intepirdine for about $5 million, and house each in its own subsidiary. He had spent seven years at a biotech hedge fund learning which assets were underpriced, and he had the backing of the fund.

vAxovant and the first payouts

Axovant, the Alzheimer's subsidiary, went public in 2015 and raised about $315 million, reaching a valuation of nearly $3 billion with only eight employees. Wikipedia says Ramaswamy reported more than $37 million in capital gains that year. In 2017 intepirdine failed a large trial and the stock fell about 75% in a day. Forbes notes that later Roivant drug candidates did better. SoftBank put $1.1 billion into Roivant that year, and in 2019 the sale of stakes in five subsidiaries to Sumitomo Dainippon Pharma reportedly brought him $175 million in capital gains.

viLeaving Roivant, Strive, politics

He stepped down as CEO in January 2021 and as chairman in February 2023. Wikipedia says he still holds about 7.17% of Roivant. Forbes says positive Phase 3 results for brepocitinib sent the stock up in late 2025. He co-founded Strive Asset Management in 2022, which Wikipedia says raised about $20 million from investors including Peter Thiel, JD Vance and Bill Ackman, and left its chairmanship to run for president. He finished fourth in the 2024 Iowa caucuses and endorsed Donald Trump. He won the May 2026 Republican primary for Ohio governor.

viiWhere it stands

Forbes lists his net worth at $2.3 billion as of October 11, 2026, ranking him 1,827th and self-made. The figure is mostly his Roivant stake. Two former Strive employees have sued him and the firm. In August 2026 a federal judge let key whistleblower claims in one suit go forward. The claims are the plaintiffs' allegations, he and Strive deny them, and no finding has been made.

Can you replicate their success?

Partly

Parts of this route can be copied. Reading a niche well enough to see which assets are mispriced is a skill, and so is structuring each asset as its own company. The funding was different. A well-paid fund job gave him savings, a backer and access to investors, and Roivant's early capital came mainly from QVT and others, not from his own pocket. That kind of backing is rare, and it isn't open to someone without a fund behind them.

Required conditions

1 Years inside a specialist investment fund, with a record the fund trusts

2 A sponsor willing to put roughly $100 million behind an unproven holding company

3 A market that lets early-stage drug assets list at large valuations

4 A way to sell down or hold stakes in subsidiaries as they succeed

The coded evidence

Thirteen groups, every claim sourced

Feeds cost of failure

Parent Occupations

Medium

Father an engineer at General Electric; mother a geriatric psychiatrist who worked for Merck and Schering-Plough.

↗ en.wikipedia.org

Parental Self Employment

Medium

Neither parent was self-employed.

Both parents are described as employees of large companies.

↗ en.wikipedia.org

Parent Education

Low

Father an engineer and mother a physician-psychiatrist, so both had professional training; degrees not detailed in sources consulted.

↗ en.wikipedia.org

Structural context

founder lens · venture capital

The cost-of-failure score comes from this person's own money and circumstances. But who they were in America carried its own weight, the same way their household or income did, and it shaped how hard the path was just as much. That part isn't in the cost-of-failure number. It's here instead.

tailwindman

Men founded the companies that took nearly all the venture funding and almost every top outcome, a tailwind that never shows up in one person's own circumstances.

↗ techcrunch.com

mixedimmigrant background

Immigrants and their children are overrepresented among America's biggest companies, as founders and as senior leaders. They got there through the visa, credential, and network hurdles that make the path harder to even start down.

↗ forbes.com

Among the people recorded here — men: 225. Representation here is who reached these outcomes, not equal odds of reaching them.